Assess response to IO and targeted therapy with a
single draw 4-10 weeks after starting treatment.²

Predict treatment response before standard imaging.¹

Important note: Guardant360 Response was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

IO, immunotherapy.
*Samples are accepted up to 20 weeks after baseline blood draw.

Home Screening Monitoring: MRD Monitoring: Treatment Response Treatment Selection

Assess response to IO and targeted therapy with a single draw 4-10 weeks after starting treatment.²

Assess response to IO and targeted therapy with a
single draw 4-10 weeks after starting treatment.²